Paid Clinical Trials St. Louis
Discover 1,374 paid clinical trials in St. Louis, Missouri. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Magnetic Resonance Imaging
Photon Beam Radiation Therapy
Questionnaire Administration
Temozolomide
Dasatinib & QuercetinDasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT05838560
Conditions
Schizophrenia
Treatment Resistant Depression
Aging, Premature
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
Dasatinib
quercetin
Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor:
Allogene Therapeutics
Location:
Code:
NCT06500273
Conditions
Large B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemacabtagene ansegedleucel
ALLO-647
Fludarabine
Cyclophosphamide
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
RavulizumabStudy of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sponsor:
Alexion Pharmaceuticals, Inc.
Location:
Code:
NCT06291376
Conditions
Immunoglobulin A Nephropathy
IgAN
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ravulizumab
Placebo
CA-4948, FOLFOX, PD-1 Inhibitor, TrastuzumabCA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT05187182
Conditions
Gastric Cancer
Esophageal Cancer
Stomach Cancer
Esophagus Cancer
Gastroesophageal Junction Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CA-4948
Nivolumab
Pembrolizumab
Trastuzumab
mFOLFOX7
PDA TreatmentPREEMIE: Study for Treatment of PDA in Premature Infants
Sponsor:
Merit Medical Systems, Inc.
Location:
Code:
NCT06587282
Conditions
Patent Ductus Arteriosus (PDA)
Eligibility Criteria
Sex: All
Age: 5+
Healthy Volunteers: Not accepted
Interventions
Bloom Micro Occluder System
SonobiopsySonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT05281731
Conditions
Glioblastoma
Glioblastoma Multiforme
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sonobiopsy
Research blood
Cancer Personalized Profiling
Definity®
ZEN003694 with CapecitabineTesting the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05803382
Conditions
Metastatic Colorectal Carcinoma
Metastatic Malignant Solid Neoplasm
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Carcinoma
Unresectable Malignant Solid Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BET Bromodomain Inhibitor ZEN-3694
Biopsy Procedure
Biospecimen Collection
Capecitabine
Computed Tomography
Medication OptimizationThe Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
Sponsor:
University of Michigan
Location:
Code:
NCT05858320
Conditions
Heart Failure
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
SmartHF application
AZD8205A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
Sponsor:
AstraZeneca
Location:
Code:
NCT05123482
Conditions
Breast Cancer
Biliary Tract Carcinoma
Ovarian Cancer
Endometrial Cancer
Squamous Non-Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AZD8205
AZD8205 and AZD2936 (Rilvegostomig)
AZD8205 and AZD5305 (saruparib)
AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)